[一种CRISPR/Cas方法来治疗β-血球蛋白病变]
Megane Brusson1, Annarita Miccio1
1Institut Imagine, Inserm UMR1163, université Paris Cité, Paris, France.
Medecine sciences : M/S
|January 31, 2025
概括
CRISPR/Cas9基因编辑在患有严重贫血症的患者中重新激活胎儿血红蛋白,如β-血症和状细胞疾病. 这种疗法显示出有前途的临床改善,目前正在研究长期的安全性和降低成本.
科学领域:
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- β-hemoglobinopathies是由于成年人血红蛋白合成受损而导致的衰弱的遗传性贫血病.
- 目前的治疗重点是促进胎儿血红蛋白 (HbF) 表达,以补偿缺陷的成人血红蛋白.
- 基因编辑CRISPR/Cas9提供了一种新的方法来基因纠正这些条件.
研究的目的:
- 评估CRISPR/Cas9基因编辑在重新激活胎儿血红蛋白表达中的有效性.
- 评估使用Casgevy®治疗治疗的严重β-血球蛋白病变患者的临床结果.
- 确定未来治疗开发的领域,包括安全性,基因毒性和成本效益.
主要方法:
- 使用CRISPR/Cas9.9进行患者造血干细胞/原生细胞的ex vivo遗传修饰.
- 在体内评估胎儿血红蛋白重新激活和编辑效率在红状腺后代.
- 在治疗后对患者表型和血红蛋白水平进行临床评估.
主要成果:
- 超过70名患有严重β-血症和状细胞病的患者接受了Casgevy®治疗.
- 在造血细胞中观察到高基因编辑效率.
- 显著的临床表型改善,大多数患者的血红蛋白水平正常化或接近正常化.
结论:
- 基因编辑CRISPR/Cas9是一种强大的治疗策略,用于beta-hemoglobinopathies,显示出显著的临床益处.
- Casgevy®疗法显示出高编辑效率和积极的临床结果,为患者提供了希望.
- 进一步的研究是必要的,以确认长期的安全性,尽量减少基因毒性,并降低治疗成本.
更多相关视频
10:21Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
Published on: January 5, 2018
13.0K
08:14Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
Published on: October 3, 2019
12.1K
相关概念视频
01:59CRISPR
49.1K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
49.1K
02:31Homologous Recombination
50.1K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.1K
02:53CRISPR and crRNAs
16.6K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.6K